Hongcheng Biopharma focuses on developing revolutionary protein, antibody, ADC and RNA medicines to treat diseases in the fields of tumor immunity, autoimmunity and fibrosis. We have established hybridoma, bioengineering, antibody drug conjugates, pharmacology platforms to support discovery research and a CMC team to support our product development. We work with multiple companies to advance our programs. Currently, our pipeline of multispecific antibodies, ADCs, prodrugs and recombinant proteins is rapidly advancing towards the clinical stage. To accelerate our development we welcome discussion on opportunities for external cooperation to enrich our product line.